Abstract: Globally，lung cancer is the leading cause of cancerrelated death with high morbidity, mortality and poor prognosis. The epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI），a means of molecularly targeted therapy，offers a novel approach for the treatment of patients with NSCLC harboring EGFR mutation effectively. However，the problem of EGFRTKI resistance exists inevitably. A number of promising strategies based on different mechanisms have now been evaluated in phase Ⅰ／Ⅱ trials. These include EGFR-TKI discontinuation，EGFR-TKI continuing，EGFR-TKI+local treatment，EGFR+other molecularly targeted drugs，EGFR-TKI+chemotherapy，EGFR-TKI rechallenge，chemotherapy，chemotherapy+other molecularly targeted drugs and EGFR-TKI+immunotherapy. The purpose of this paper will draw a summary on the progress of treatments in patients with NSCLC harboring EGFR-TKI resistance.